ACTG 219: PEDIATRIC LATE OUTCOMES PROTOCOL

ACTG 219：儿科晚期结果方案

• 批准号: 7376232
• 负责人: RUSSELL B. VAN DYKE
• 金额: $ 14.51万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376232
• 关键词: ACTG; 219; PEDIATRIC; LATE; OUTCOMES

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Study to describe the way in which HIV-infection (AIDS) and new therapies affect the developing child, to assess the effect of perinatal transmission studies on the ultimately uninfected infant and to follow the overall survival, morbidity and quality of life of ultimately HIV infected as well as uninfected pediatric patients.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。研究描述艾滋病毒感染（艾滋病）和新疗法影响发育中儿童的方式，评估围产期传播研究对最终未感染婴儿的影响，并跟踪最终艾滋病毒感染者的总体生存率、发病率和生活质量以及未感染的儿科患者。